Abilify drives modest pharma growth at Otsuka
This article was originally published in Scrip
Executive Summary
Net pharmaceutical sales at Otsuka Pharmaceutical rose by 2% to ¥545.3 billion ($6.55 billion) in the nine months to 31 December, accounting for two-thirds of the business of parent Otsuka Holdings and driven by US growth for the atypical antipsychotic Abilify (aripiprazole).